AnteoTech Strengthens Commercial Momentum Across Battery and Life Sciences Businesses
AnteoTech Ltd (ASX: ADO) has reported strong commercial and technical progress during the June 2026 quarter, supported by major advancements across its Advanced Battery Technologies and Life Sciences divisions alongside a significantly stronger balance sheet. The Company completed independent commercial-format validation of its Ultranode™ 95 high-silicon anode, demonstrating energy density exceeding 390 Wh/kg and more than 300 charge-discharge cycles, reinforcing its suitability for defence drone battery applications. AnteoTech also launched its new Anteo C™ battery materials product, expanded strategic partnerships in South Korea and Japan, and advanced negotiations on joint development agreements with US battery manufacturers. In Life Sciences, the Company completed the initial phase of its collaborative CLIA diagnostic development program with a global healthcare company and expanded distribution through Japan's Cosmo Bio. The successful exercise of listed options raised approximately AU$10.0 million, increasing quarter-end cash reserves to AU$11.2 million, providing additional funding to accelerate commercialisation across both business segments.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
AnteoTech Strengthens Commercial Momentum Across Battery and Life Sciences Businesses
AnteoTech Ltd (ASX: ADO) has reported strong commercial and technical progress during the June 2026 quarter, supported by major advancements across its Advanced Battery Technologies and Life Sciences divisions alongside a significantly stronger balance sheet. The Company completed independent commercial-format validation of its Ultranode™ 95 high-silicon anode, demonstrating energy density exceeding 390 Wh/kg and more than 300 charge-discharge cycles, reinforcing its suitability for defence drone battery applications. AnteoTech also launched its new Anteo C™ battery materials product, expanded strategic partnerships in South Korea and Japan, and advanced negotiations on joint development agreements with US battery manufacturers. In Life Sciences, the Company completed the initial phase of its collaborative CLIA diagnostic development program with a global healthcare company and expanded distribution through Japan's Cosmo Bio. The successful exercise of listed options raised approximately AU$10.0 million, increasing quarter-end cash reserves to AU$11.2 million, providing additional funding to accelerate commercialisation across both business segments.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au